Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 32 Growth opportunities supported by strong global presence in both sales and manufacturing Employees in sales regions¹ Global manufacturing setup Denmark (~9,800 employees) Diabetes and biopharmaceutical API production Filling and packaging Moulding and assembly Tablet production Kaluga, Russia (~265 employees) Filling Assembly Packaging North America Operations: ~4,800 Region Africa, Asia, Middle-East West Lebanon, NH, USA (~180 employees) and Oceania (AAMEO): ~4,700 Biopharmaceutical API production Region China: ~3,200 Region Europe: ~2,900 Clayton, NC, USA (~1,100 employees) Region Japan & Korea: ~1,200 Region Latin America: ~940 Total non-HQ/manufacturing employees: ~18,700¹ Koriyama, Japan (~65 employees) Packaging Diabetes API production Filling Assembly Packaging of above Chartres, France (~1,100 employees) Filling Assembly Packaging Tianjin, China (~1,000 employees) Filling Assembly Packaging Montes Claros, Brazil (~1,000 employees) Filling Assembly Packaging Tizi Ouzou, Algeria (~200 employees) Tablet production 1 Employees represent full-time equivalents in Novo Nordisk's sales regions (excludes all other employees in headquarter, research sites and manufacturing sites) as of March 2018 changing diabetes® novo nordisk

View entire presentation